XML 101 R68.htm IDEA: XBRL DOCUMENT v3.6.0.2
Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Novartis (Details) - Novartis [Member] - Subsequent Event [Member]
$ in Millions
1 Months Ended
Jan. 31, 2017
USD ($)
shares
Collaborative Arrangement and Licensing Agreement [Abstract]  
Shares issued (in shares) | shares 1,631,435
Proceeds from sale of common stock $ 100
Additional amount of common stock required to be purchased in the future 50
Akcea [Member]  
Collaborative Arrangement and Licensing Agreement [Abstract]  
Upfront payment received 75
Portion of upfront payment retained 60
Portion of upfront payment paid as a sublicense fee 15
License fee receivable per drug $ 150
Percentage of license fees, milestone payments and royalties paid as sublicense fee 50.00%
Akcea [Member] | AKCEA-APO(a)-L [Member]  
Collaborative Arrangement and Licensing Agreement [Abstract]  
Maximum amount of payments receivable for milestones $ 600
Royalty percentage received on sales of drug 20.00%
Akcea [Member] | AKCEA-APOCIII-L [Member]  
Collaborative Arrangement and Licensing Agreement [Abstract]  
Maximum amount of payments receivable for milestones $ 530
Royalty percentage received on sales of drug 20.00%